arrow
G

Giulia Fulci

gsk
H指数:26
被引数:2,689

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

患者报告的结果:比较belantamab mafodotin联合pomalidomide和地塞米松与 bortezomib联合pomalidomide和地塞米松在复发或难治性多发性骨髓瘤患者中的疗效(DREAMM-8):一项III期、开放标签、随机对照试验

2025-11-030
PRE
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

贝兰他单抗马福替尼联合泊马利度胺和地塞米松与泊马利度胺联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤:在接受过包含来那度胺的1线先前治疗的患者亚组分析

BLOOD
IF23.1
2024-11-053
PRE
High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
2022-02-150
PRE
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
2021-03-178
OAAI